Conversely, a phase I/II clinical trial testing the durvalumab and olaparib combination showed minimal increase in both the STING protein and mRNA levels in post-treatment tumor biopsies, yet those samples had increase in CXCL10 and other immune mediators by RNA-seq (15). Here, CXCL10 is linked to neoplasm.